Profile data is unavailable for this security.
About the company
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
- Revenue in INR (TTM)27.76bn
- Net income in INR-5.01bn
- Incorporated1999
- Employees2.74k
- LocationWockhardt LtdWockhardt TowersBandra Kurla Complex, Bandra (East)MUMBAI 400051IndiaIND
- Phone+91 2 226534444
- Fax+91 2 226523905
- Websitehttp://www.wockhardt.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 46.74bn | 1.40k | 24.02 | -- | 17.67 | 2.55 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
Shilpa Medicare Ltd | 11.23bn | -6.71m | 52.45bn | 1.03k | -- | -- | 49.32 | 4.67 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
Orchid Pharma Ltd | 8.12bn | 1.25bn | 53.43bn | 838.00 | 36.97 | -- | 33.62 | 6.58 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 67.41bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
F D C Ltd | 19.16bn | 2.90bn | 73.35bn | 6.37k | 25.56 | -- | 22.32 | 3.83 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
Marksans Pharma Ltd | 21.03bn | 3.17bn | 76.15bn | 1.40k | 23.84 | -- | 19.67 | 3.62 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
Strides Pharma Science Ltd | 39.53bn | -1.52bn | 77.53bn | 2.85k | -- | -- | 131.06 | 1.96 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
Procter & Gamble Health Ltd | 12.37bn | 2.27bn | 78.04bn | 1.41k | 34.43 | 9.68 | 30.91 | 6.31 | 136.55 | 136.55 | 745.23 | 485.49 | 1.15 | 2.51 | 10.40 | 8,791,756.00 | 21.02 | -- | 27.67 | -- | 69.97 | -- | 18.32 | -- | 2.79 | 383.03 | 0.0132 | -- | 10.34 | -- | 19.19 | -- | -- | -- |
Wockhardt Ltd | 27.76bn | -5.01bn | 87.83bn | 2.74k | -- | -- | -- | 3.16 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 97.87bn | 1.57k | 30.87 | -- | 26.18 | 6.19 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
Granules India Ltd | 45.26bn | 3.95bn | 100.43bn | 3.65k | 25.40 | -- | 16.79 | 2.22 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 101.60bn | 777.00 | 23.34 | -- | 20.75 | 6.23 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 102.53bn | 407.00 | -- | -- | -- | 96.11 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
Glenmark Life Sciences Ltd | 23.68bn | 5.19bn | 102.87bn | 1.82k | 19.82 | -- | 18.06 | 4.34 | 42.36 | 42.36 | 193.15 | -- | -- | -- | -- | 12,982,110.00 | -- | -- | -- | -- | 55.92 | -- | 21.93 | -- | -- | 538.47 | -- | -- | 1.79 | -- | 11.52 | -- | -- | -- |
Jubilant Pharmova Ltd | 66.22bn | 378.60m | 107.85bn | 1.03k | 281.08 | -- | 18.40 | 1.63 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
Eris Lifesciences Ltd | 18.61bn | 3.86bn | 119.93bn | 3.55k | 31.08 | -- | 22.10 | 6.44 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.22m | 1.45% |
ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 1.93m | 1.26% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 887.04k | 0.58% |
Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Mar 2024 | 870.41k | 0.57% |
Samco Asset Management Pvt. Ltd.as of 31 Mar 2024 | 663.00k | 0.43% |
Invesco Asset Management (India) Pvt Ltd.as of 31 Mar 2024 | 580.27k | 0.38% |
BlackRock Fund Advisorsas of 04 Apr 2024 | 546.25k | 0.36% |
Norges Bank Investment Managementas of 31 Dec 2023 | 351.08k | 0.23% |
SSgA Funds Management, Inc.as of 04 Apr 2024 | 278.51k | 0.18% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 232.11k | 0.15% |